Previous close | 22.79 |
Open | 22.82 |
Bid | 22.90 x 900 |
Ask | 22.92 x 1300 |
Day's range | 21.02 - 22.98 |
52-week range | 5.84 - 24.42 |
Volume | |
Avg. volume | 16,871,769 |
Market cap | 1.672B |
Beta (5Y monthly) | 0.63 |
PE ratio (TTM) | 20.82 |
EPS (TTM) | 1.10 |
Earnings date | 02 Nov 2022 - 07 Nov 2022 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | 16 May 2022 |
1y target est | N/A |
Many investors likely hadn't heard of drugmaker Siga Technologies (NASDAQ: SIGA) even just a month ago. Siga, which owns a monkeypox treatment in Tpoxx, is likely to experience a surge in sales. The big question for investors: Is Siga's stock destined to go even higher or has it already peaked?
A vaccine maker, a therapeutics company, and a medical lab could suit a variety of investor risk profiles.
SIGA Technologies, maker of the only available monkeypox treatment, is working to ramp up manufacturing for broader global distribution.